BIXT · Bioxytran, Inc
$0.02
0.00 (-3.96%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations.”View the 10-Q filed May 15, 2026
Market Cap
$2.59M
Shares
114.20M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$191.08K
-22.5%
FY2017
Net Income
-$2.12M
+10.3%
FY2025
Gross Margin
45.58%
-15.4pp
FY2017
Operating Margin
-162.55%
+109.8pp
FY2017
Diluted EPS
-$0.02
0%
FY2025
Operating Cash Flow
-$526.46K
-38.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | $191.08K | $246.5K | $255.82K | $275.62K | $417.34K | $312.9K | $76.3K | $16.13K | — | |
| $94.27K | — | — | — | — | — | — | — | — | $103.98K | $96.3K | $135.69K | $165.98K | $197.39K | $121.92K | $19.07K | $4034 | — | |
| $83.52K | — | — | — | — | — | — | — | — | $87.1K | $150.19K | $120.14K | $109.64K | $219.95K | $190.98K | $57.22K | $12.1K | — | |
| — | — | — | — | — | — | — | — | — | 45.58% | 60.93% | 46.96% | 39.78% | 52.7% | 61.04% | 75% | 74.99% | — | |
| — | $454K | $112.34K | $1.15M | $1.28M | $2.01M | $544.52K | — | — | — | — | — | — | — | — | — | — | — | |
| $718.43K | $648.23K | $1.17M | $1.4M | $834.68K | $1.61M | $476.32K | $507.27K | $215.11K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $397.69K | $821.47K | $2.21M | $1.39M | $2.19M | $2.48M | $4.49M | $341.13K | — | |
| $11.8K | $11.54K | $7950 | $8285 | $3644 | — | -$10K | — | — | — | — | — | — | — | — | — | — | — | |
| $3.26M | $1.84M | $2.22M | $3.8M | $2.44M | $4.21M | $1.27M | $1.63M | $215.11K | $397.69K | $821.47K | $2.21M | $1.39M | $2.19M | $2.48M | $4.49M | — | — | |
| -$3.26M | -$1.84M | -$2.22M | -$3.8M | -$2.44M | -$4.21M | -$1.27M | -$1.63M | -$215.11K | -$310.59K | -$671.28K | -$2.09M | -$1.28M | -$1.97M | -$2.29M | -$4.43M | -$329.03K | — | |
| — | — | — | — | — | — | — | — | — | -162.55% | -272.33% | -817.88% | -464.67% | -472.64% | -731.76% | -5803.56% | -2039.62% | — | |
| $138.89K | $134.31K | $84.24K | $193.19K | — | $2.02M | $1.01M | $41.85K | $3722 | $7800 | $7800 | $7800 | $7800 | $12.66K | — | — | — | — | |
| $5740 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $2052 | $925 | — | |
| $421.99K | -$280.57K | -$156.94K | -$762.57K | -$229.97K | -$313.61K | -$1.27M | -$227.01K | -$81.31K | -$7800 | -$25.48K | -$7800 | -$66.2K | $193.94K | -$3546 | -$4395 | -$7437 | — | |
| -$2.84M | -$2.12M | -$2.38M | -$4.56M | -$2.67M | -$4.53M | -$2.54M | -$1.86M | -$296.42K | — | -$696.76K | -$2.1M | -$1.35M | -$1.78M | — | — | — | — | |
| — | — | — | — | — | — | — | — | $400 | — | — | — | — | — | — | — | — | — | |
| -$2.84M | -$2.12M | -$2.37M | -$4.47M | -$2.47M | -$4.03M | -$2.54M | -$1.86M | -$296.42K | -$318.39K | -$696.76K | -$2.1M | -$1.35M | -$1.78M | -$2.29M | -$4.43M | -$336.47K | -$276.35K | |
| — | — | — | — | — | — | — | — | — | -166.63% | -282.67% | -820.93% | -488.69% | -426.16% | -732.9% | -5809.32% | -2085.73% | — | |
| — | — | -$13.32K | -$90.26K | -$193.37K | -$496.3K | -$61.91K | — | — | — | — | — | — | — | — | — | — | — | |
| -$3.32M | — | — | — | — | -$4.03M | -$2.48M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.02 | -$0.02 | -$0.03 | -$0.02 | -$0.04 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.02 | -$0.02 | -$0.03 | -$0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 91.84M | 138.6M | 133.97M | 112.71M | 106.25M | 93.97M | 85.6M | 85.1M | 39.49M | 26.51M | 10.08M | 4.45M | 3.75M | 131.91M | 70.4M | — | — |
| shares | — | 91.84M | 138.6M | 133.97M | 112.71M | 106.25M | 93.97M | 85.6M | 85.1M | 39.49M | 26.51M | 10.08M | 4.45M | 3.75M | 131.91M | 70.4M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 125 similar-size Biotechnology companies (of 522 listed).